Loading...
Please wait, while we are loading the content...
Heart Failure with Preserved Ejection Fraction: Pathophysiology and Emerging Therapies
| Content Provider | Scilit |
|---|---|
| Author | Borlaug, Barry A. |
| Copyright Year | 2010 |
| Description | Journal: Cardiovascular Therapeutics Approximately half of patients with heart failure (HF) have a preserved ejection fraction (HFpEF). Morbidity and mortality are similar to HF with reduced EF (HFrEF), yet therapies with unequivocal benefit in HFrEF have not been shown to be effective in HFpEF. Recent studies have shown that the pathophysiology of HFpEF, initially believed to be due principally to diastolic dysfunction, is more complex. Appreciation of this complexity has shed new light into how HFpEF patients might respond to traditional HF treatments, while also suggesting new applications for novel therapies and strategies. In this review, we shall briefly review the pathophysiologic mechanisms in HFpEF, currently available clinical trial data, and finally explore new investigational therapies that are being developed and tested in ongoing and forthcoming trials. |
| Ending Page | e21 |
| Starting Page | e6 |
| ISSN | 2573508X |
| e-ISSN | 17555922 |
| DOI | 10.1111/j.1755-5922.2010.00133.x |
| Journal | Cardiovascular Therapeutics |
| Issue Number | 4 |
| Volume Number | 29 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2010-03-29 |
| Access Restriction | Open |
| Subject Keyword | Journal: Cardiovascular Therapeutics Cardiology and Cardiovascular Diseases Heart Failure with Preserved Ejection Fraction |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology Pharmacology (medical) Cardiology and Cardiovascular Medicine |
